www.efpia.eu

The pharmaceutical industry in the EU

The transatlantic industry today

The US is the biggest individual market for the European pharmaceutical industry

EFPIA Brussels OfficeLeopold Plaza Building * Rue du Trône 108 B-1050 Brussels * Belgium

Tel: + 32 (0)2 626 25 55 * Fax: + 32 (0)2 626 25 66www.efpia.eu * info@efpia.eu

The EU – US Transatlantic Trade and Investment Partnership (TTIP):Impact on EU economy, society and patients

EU EXPORTS TO

THE EU, 2014 MARKETS OUTSIDE

30%

UNITED STATES

11%

SWITZERLAND

5%

CHINA

6%

RUSSIA

JAPAN

6%

42%

OTHERS

€118 BILLIONTOTAL

60%OF US PHARMA

ARE FROM THE EUIMPORTS

OUTOF THE TOP

ARE FROM

PHARMACOMPANIES

8 10

EUROPEOR THE US

75%OF GLOBAL R&D

IN THE EU & USIN LIFE-SCIENCE TAKES PLACE

80%OF GLOBAL

OF PHARMASALES

IN SUPPORTING INDUSTRIES2 .0 MIL L ION

2.6 MILLION

EU JOBS

0.6 MILLIONIN PHARMA INDUSTRY

EVERY JOB IN THE

SUPPORTS PHARMACEUTICAL INDUSTRY

STRONG ECONOMIC

FOOTPRINT

3 OTHER JOBS

+26,000IN THE EU PHARMA INDUSTRY

+5% INCREASE

PHARMACONTRIBUTES

TO THE EU ECONOMYSIGNIFICANTLY

EU GOODS

EXPORTS

6%EU MANUFACTURING

P R O D U CT I O N

3%

PRODUCTIVITY IS

THAN THE MANUFACTURING AVERAGE

2.5 TIMES HIGHER

HIGHLYQUALIFIED

HIGHLYPRODUCTIVE

INCREASE IN JOBS

IN 2000 2013

Key findings* Key findings* Opportunities in TTIP for the Pharmaceutical Industry

* * The study, carried out by Copenhagen Economics and commissioned by EFPIA, relies on key estimates of the impact and reduction potential of non-tariff barriers on transatlantic trade in pharmaceuticals as estimated by the European Commission and CEPR.

* Findings are drawn from a study carried out by Copenhagen Economics for EFPIA. The study assesses the economic impacts for the EU from an ambitious pharmaceutical chapter in TTIP

IN EU PHARMA EXPORTS

+€9 BILLION

+8,000 JOBSIN US PHARMA AFFILIATES IN THE EU

IF TTIP LOWERS FDI BARRIERS

BY 25 PER CENT

+79,000 JOBS

REDUCING FDIBARRIERS BY 25 PER CENT

AFFILIATES BY

EMPLOYMENT ININCREASES

TRANSATLANTIC

10 PER CENT

+€146 BILLIONVALUE OF EXPORTS

+€117 BILLIONVALUE OF IMPORTS

+€9 BILLION

+€4 BILLION

OVERALL

PHARMACEUTICAL

PHARMACEUTICAL

OVERALL

Regulatory cooperation:

Intellectual Property:

BENEFITS FOR EU PATIENTS

Market access:

+ HORIZONTAL REGULATORY MEASURES AND COOPERATION

TTIP can reinforce commitment to shared high level Intellectual Property (IP) principles already in place in both the EU and the US and promote these standards in their respective trade agendas

Harmonisation of clinical trial results data fields can reduce duplicative submissions of the same data, which creates efficiencies and facilitates information sharing

TTIP can help promote predictable and transparent pricing and reimbursement processes, supporting access to medicines for patients in Europe

A harmonised approach to the submission of CMC changes would reduce the administrative burdens for both companies and regulatory agencies

Common procedures for submitting paediatric plans can reduce duplicative and unnecessary testing on children and accelerate delivery of newpaediatric medicines

FASTER ACCESS

MEDICINESTO INNOVATIVE

INCREASED CHOICE

& HEALTH CARE SYSTEMSFOR EU PATIENTS

FREE UP RESOURCES

FOR COMPANIESAND REGULATORS

+19,000NEW HIGH VALUE JOBSIN THE EU PHARMA INDUSTRY

+60,000SUPPORTS AROUND

ADDITIONAL JOBSIN RELATED INDUSTRIES

Mutual recognition of Good Manufacturing Practices (GMP) inspections can reduce duplicative inspections of manufacturing sites on both sides of the Atlantic by up to 40%